Europese Unie - Nederlands - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - geneesmiddelen voor de behandeling van botziekten - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Europese Unie - Nederlands - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - middelen voor dermatitis, met uitzondering van corticosteroïden - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aop orphan pharmaceuticals gmbh - tetrabenazine 25 mg - tablet - 25 mg - tetrabenazine 25 mg - tetrabenazine

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dr. falk pharma gmbh - kaliumchloride 0,185 g; natriumchloride 1,4 g; macrogol 52,5 g; natriumbicarbonaat 0,715 g - poeder voor drank - macrogol 3.350 52500 mg; kaliumchloride 185 mg; natriumbicarbonaat 715 mg; natriumchloride 1400 mg - macrogol, combinations

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - glycopyrroniumbromide 0,2 mg - oplossing voor injectie - 0,20 mg/ml - glycopyrroniumbromide 0.2 mg/ml - glycopyrronium bromide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - somatostatineacetaathydraat - eq. somatostatine 250 µg - poeder en oplosmiddel voor oplossing voor injectie - 250 µg - somatostatineacetaathydraat - somatostatin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - somatostatineacetaathydraat - eq. somatostatine 3 mg - poeder en oplosmiddel voor oplossing voor infusie - 3 mg - somatostatineacetaathydraat - somatostatin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - urokinase 100000 ie - poeder voor oplossing voor injectie/infusie - 100.000 iu - urokinase 100000 ie - urokinase

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eumedica pharmaceuticals gmbh - urokinase 600000 ie - poeder voor oplossing voor injectie/infusie - 600.000 iu - urokinase 600000 ie - urokinase

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kwizda pharma gmbh - althaea officinalis l., wortel, vloeibaar extract water 1-12_14 55,3 mg/ml; thymus vulgaris l. - thymus zygis loefl. ex l. (ph.eur.), kruid, droog water extract 7-13_1 7,81 mg/ml - siroop - thymus vulgaris l. - thymus zygis loefl. ex l. (ph.eur.), kruid, droog water extract 7-13_1 7.805 mg/ml; althaea officinalis l., wortel, vloeibaar extract water 1-12_14 55.304 mg/ml - combinations